Lupin arm gets USFDA nod to market generic Zyvox tablets
New Delhi : Drug major Lupin said its subsidiary Gavis Pharmaceuticals has received approval from the US health regulator to market generic linezolid tablets used for treating bacterial infection in the American market.
The company's US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing.
Gavis' product is a generic version of Pharmacia and Upjohn company's Zyvox tablets, which is indicated in adults and children for treatment of certain infections caused by susceptible gram-positive bacteria.
As per IMS MAT June sales data, Zyvox tablets had US sales of USD 273.6 million.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd